Selection criteria for patch angioplasty material in carotid endarterectomy

Nur Setiawan Suroto1,2, Fedik Abdul Rantam1,3,4, Asra Al Fauzi2, Prihartini Widiyanti5, Agus Turchan2, Vega Pangaribuan2

1Doctoral Program of Medical Science, Faculty of Medicine, Universitas Airlangga, 2Department of Neurosurgery, Faculty of Medicine, Universitas Airlangga, / Dr. Soetomo General Academic Hospital, Surabaya, East Java, Indonesia, 3Stem Cell Research and Development Center, Universitas Airlangga, 4Department of Microbiology, Virology and Immunology Laboratory, Faculty of Veterinary Medicine, Universitas Airlangga, 5Biomedical Engineering Study Program, Department of Physics, Faculty of Science and Technology, Universitas Airlangga, Surabaya 60115, Indonesia.

E-mail: Nur Setiawan Suroto - nur.setiawan.suroto-2016@fk.unair.ac.id; Fedik Abdul Rantam - fedik.ar@gmail.com; *Asra Al Fauzi - asra.al@fk.unair.ac.id, Prihartini Widiyanti - pwidiyanti@fst.unair.ac.id; Agus Turchan - agusturchan@yahoo.com; Vega Pangaribuan - vegasolagracia@gmail.com

INTRODUCTION

Carotid endarterectomy (CEA) remains a mainstay treatment for carotid stenosis since it was first conducted in 1954 by Eastcott et al.14 The indication of this procedure is for symptomatic patient with stenosis >50% and asymptomatic patients with stenosis >60%.36 However, primary CEA is often associated with restenosis, which can lead to multiple intervention and recurrent stroke.9,26 Other techniques that are widely conducted are patch angioplasty CEA. Several systematic reviews have shown that patch angioplasty can lower perioperative morbidity, long-term risk of stroke, and restenosis compared to the primary CEA.10,20,44

There are several materials that can be used for patch angioplasty, those are autologous vein, prosthetic patches (polytetrafluoroethylene [PTFE], Dacron, polyurethane, and polyester), and...
biologic patches (bovine pericardium and decellularized extracellular matrix). However, the outcome of different patch materials seemed to be similar in terms of short- and long-term results.[46]

Vascular surgeons have not been able to identify the specific and clear guidance in choosing materials for patch angioplasty. This systematic review aimed to find the ideal criteria for patch angioplasty in CEA and whether the materials that were studied have fulfilled the ideal criteria or not.

MATERIALS AND METHODS

Literature search

The search strategy was in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidance. We performed a literature search in PubMed and SCOPUS in June 8, 2021. The keywords that were used are carotid AND Endarterectomy AND Patch. The detailed search terms can be seen in the Supplementary Table 1. The search was conducted by two independent investigators. Any disagreement will be discussed by the two investigators.

Eligibility criteria

The articles included in this research met the following criteria: (1) experimental procedure in human carotid artery, (2) mentioned the ideal criteria for selecting patch angioplasty material, (3) revealed the source of the patch material, (4) parameter used to evaluate complications, (5) examined a single type of material during study, and (6) the full text is available in English. Any duplicated unavailable full texts, review papers, case reports, case series, or abstract-only papers are not included in our review.

Data extraction

Two reviewers blind to each other independently extracted the relevant data from the included studies. Any disagreements will be resolved through discussion among the two reviewers. The data that were obtained from the full-text review are author, year of publication, number of subjects, and material that were used, ideal criteria for patch angioplasty material, time of follow-up, complications observed, and fulfillment of the ideal criteria.

RESULTS

The search engine PubMed and SCOPUS provide a total of 784 articles. Duplications were found using EndNote X9, excluding 65 articles. Screening of title and abstract by our reviewers excluded 654 articles. Additional 42 full-text articles were excluded due to its inability to fulfill the eligibility criteria; thus, 23 articles were included in our study [Figure 1].

Figure 1: PRISMA flow diagram for the selection of studies in systematic review.
### Table 1: Ideal criteria of patch material in the included studies

| Criteria                                                                 | McCready et al. (2021) | McCready et al. (2005) | Ladowski and Ladowski (2011) | Munderheim et al. (2007) | AbsiRahma et al. (2003) | AbsiRahma et al. (2005) | Archie (1987) | Archie (1986) | Bosi et al. (2005) | Bosi et al. (2001) | Dansiani et al. (2001) | Recosel et al. (2000) | Meyre and Windschell (1999) | Eikelboom et al. (1994) | Pfeffer et al. (1993) | Rhodes (1993) | Myers et al. (1994) | Katz et al. (1994) | De Letter et al. (1994) | LeGrand and Linehan (1990) | Clagett et al. (1989) | Ham (1987) | Scoring |
|-------------------------------------------------------------------------|-------------------------|-------------------------|------------------------------|--------------------------|--------------------------|--------------------------|----------------|----------------|----------------|----------------|--------------------------|--------------------------|--------------------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|
| Physical characteristics                                                | v                       | v                       | v                            | v                        | v                        | v                        | y             | y             | y              | y              | v                        | v                        | v                        | v              | v              | v              | v              | v              | v              | v              | v              |
| Easy to handle                                                          | v                       | v                       | v                            | v                        | v                        | v                        | y             | y             | y              | y              | v                        | v                        | v                        | v              | v              | v              | v              | v              | v              | v              | v              |
| Resistant to bleeding                                                   | v                       | v                       | v                            | v                        | v                        | v                        | y             | y             | y              | y              | v                        | v                        | v                        | v              | v              | v              | v              | v              | v              | v              | v              |
| Easy to close                                                           | v                       | v                       | v                            | v                        | v                        | v                        | y             | y             | y              | y              | v                        | v                        | v                        | v              | v              | v              | v              | v              | v              | v              | v              |
| Strong flow risk of rupture                                             | v                       | v                       | v                            | v                        | v                        | v                        | y             | y             | y              | y              | v                        | v                        | v                        | v              | v              | v              | v              | v              | v              | v              | v              |
| Appearance on ultrasound                                                | v                       | v                       | v                            | v                        | v                        | v                        | y             | y             | y              | y              | v                        | v                        | v                        | v              | v              | v              | v              | v              | v              | v              | v              |
| Through coverage                                                        | v                       | v                       | v                            | v                        | v                        | v                        | y             | y             | y              | y              | v                        | v                        | v                        | v              | v              | v              | v              | v              | v              | v              | v              |
| Safety                                                                  | v                       | v                       | v                            | v                        | v                        | v                        | y             | y             | y              | y              | v                        | v                        | v                        | v              | v              | v              | v              | v              | v              | v              | v              |
| Resistant to infection                                                  | v                       | v                       | v                            | v                        | v                        | v                        | y             | y             | y              | y              | v                        | v                        | v                        | v              | v              | v              | v              | v              | v              | v              | v              |
| No immunologic reaction                                                 | v                       | v                       | v                            | v                        | v                        | v                        | y             | y             | y              | y              | v                        | v                        | v                        | v              | v              | v              | v              | v              | v              | v              | v              |
| Less bleeding                                                           | v                       | v                       | v                            | v                        | v                        | v                        | y             | y             | y              | y              | v                        | v                        | v                        | v              | v              | v              | v              | v              | v              | v              | v              |
| Hemocompatible/low rate thrombosis                                       | v                       | v                       | v                            | v                        | v                        | v                        | y             | y             | y              | y              | v                        | v                        | v                        | v              | v              | v              | v              | v              | v              | v              | v              |
| Contribution to hemodynamic                                             | v                       | v                       | v                            | v                        | v                        | v                        | y             | y             | y              | y              | v                        | v                        | v                        | v              | v              | v              | v              | v              | v              | v              | v              |
| Mechanical resistance                                                  | v                       | v                       | v                            | v                        | v                        | v                        | y             | y             | y              | y              | v                        | v                        | v                        | v              | v              | v              | v              | v              | v              | v              | v              |
| Support low flow/high turbulence                                        | v                       | v                       | v                            | v                        | v                        | v                        | y             | y             | y              | y              | v                        | v                        | v                        | v              | v              | v              | v              | v              | v              | v              | v              |
| Physical pathogenicity                                                  | v                       | v                       | v                            | v                        | v                        | v                        | y             | y             | y              | y              | v                        | v                        | v                        | v              | v              | v              | v              | v              | v              | v              | v              |
| Contribution in tissue healing                                          | v                       | v                       | v                            | v                        | v                        | v                        | y             | y             | y              | y              | v                        | v                        | v                        | v              | v              | v              | v              | v              | v              | v              | v              |
| Biodegradable                                                          | v                       | v                       | v                            | v                        | v                        | v                        | y             | y             | y              | y              | v                        | v                        | v                        | v              | v              | v              | v              | v              | v              | v              | v              |
| Prevent arterial hypertension                                           | v                       | v                       | v                            | v                        | v                        | v                        | y             | y             | y              | y              | v                        | v                        | v                        | v              | v              | v              | v              | v              | v              | v              | v              |
| Prevent endotherbalized surface                                         | v                       | v                       | v                            | v                        | v                        | v                        | y             | y             | y              | y              | v                        | v                        | v                        | v              | v              | v              | v              | v              | v              | v              | v              |
| Economically aspect                                                    | v                       | v                       | v                            | v                        | v                        | v                        | v             | v             | v              | v              | v                        | v                        | v                        | v              | v              | v              | v              | v              | v              | v              | v              |
| Readily available                                                       | v                       | v                       | v                            | v                        | v                        | v                        | y             | y             | y              | y              | v                        | v                        | v                        | v              | v              | v              | v              | v              | v              | v              | v              |
| Low cost                                                                | v                       | v                       | v                            | v                        | v                        | v                        | y             | y             | y              | y              | v                        | v                        | v                        | v              | v              | v              | v              | v              | v              | v              | v              |
| Prevent postoperative complication                                      | v                       | v                       | v                            | v                        | v                        | v                        | v             | v             | v              | v              | v                        | v                        | v                        | v              | v              | v              | v              | v              | v              | v              | v              |
| Prevent restenosis                                                      | v                       | v                       | v                            | v                        | v                        | v                        | v             | v             | v              | v              | v                        | v                        | v                        | v              | v              | v              | v              | v              | v              | v              | v              |
| Prevent pseudoaneurysm                                                  | v                       | v                       | v                            | v                        | v                        | v                        | v             | v             | v              | v              | v                        | v                        | v                        | v              | v              | v              | v              | v              | v              | v              | v              |
| Low neurologic complication                                            | v                       | v                       | v                            | v                        | v                        | v                        | v             | v             | v              | v              | v                        | v                        | v                        | v              | v              | v              | v              | v              | v              | v              | v              |
| Prevent arterial hernanous                                               | v                       | v                       | v                            | v                        | v                        | v                        | v             | v             | v              | v              | v                        | v                        | v                        | v              | v              | v              | v              | v              | v              | v              | v              |

Most referred criteria if mentioned in ≥5 studies based on the literature [33]
The simple scoring system conducted in our study was derived from a study by Bolly et al., which able to determine the ideal criteria for duraplasty material.[33] The method proposed in his review study was deemed applicable for our study.

We compiled all of the ideal criteria and grouped those criteria into physical characteristics, safety, contribution to hemodynamic performance. Review in tissue healing, economic aspect, and ability to prevent postsurgical complication. All of the findings of ideal criteria were listed into a table, and the dominant ideal criteria should have been mentioned in at least five papers. There are 10 criteria that are considered as the most dominant and the most ideal ones (mentioned ≥5 times), those are easy to handle, durable/low risk of rupture, resistant to infection, less bleeding, hemocompatible, provide endothelialized surface, readily available, prevent restenosis, prevent pseudoaneurysm, and low neurologic complication [Table 1]. The safety group becomes the most dominant criteria; due to the high possibility of complication, if the safety criteria cannot be fulfilled. Physical characteristics are also largely considered since it will affect the surgical technique and time. We also present the characteristics of the included studies [Table 2].

**DISCUSSION**

CEA for carotid artery stenosis is indicated by European Society of Cardiology for symptomatic patients with stenosis >50%, while asymptomatic patients indicated to be intervened when stenosis >60% and had high long-term risk of stroke.[19] Since the restenosis rate of primary CEA has been quite substantial, the surgical technique of CEA has been debated for many years, whether to perform a primary closure CEA or patch angioplasty CEA.[5,6] A systematic review conducted by Huizing et al., reviewed a total of 12,696 patients who underwent CEAs, and found that perioperative stroke rate and restenosis rate were lower in patch angioplasty CEA.[21] However, the quality is moderate and data on long-term stroke remain unclear. The standard of care to conduct patch angioplasty or primary closure CEA remains unclear, and the ideal materials that may provide significant advantage are still being researched.[32,35,36] Several materials that are commonly used for patch angioplasty CEA include autologous vein, synthetic materials (expanded polytetrafluoroethylene and Dacron), and biologic patches (bovine pericardium and decellularized extracellular matrix).[15,38] Nevertheless, evidence supporting the superiority of one material is lacking, and ongoing research aimed at discovering the "holy grail" material is still ongoing.[49] There is no specific guidance on the ideal criteria that needed to be fulfilled by a selected material. The ideal criteria that are being proposed in various studies usually varied and based on an institution experience. Therefore, we conducted a study determining the most dominant ideal criteria by conducting a systematic review of the literature.

Our review found that the main ideal criteria are as follows: easy to handle, durable/low risk of rupture, resistant to infection, less bleeding, hemocompatible, provides endothelialization, readily available, prevent restenosis, prevent pseudoaneurysm, and provide low neurologic complication. At present, there is no material that is able to fulfill all of those ideal criteria.

Historically, autologous veins are being favored for conducting patch angioplasty CEA, since it provides endothelialized surface, similar to the surrounding arterial tissue, easy handling, and low risk of infection. However, its apparent disadvantages, such as the extended operation duration, the probability of wound complications at the harvest site, and the likelihood of rupture and pseudoaneurysm, cannot be overlooked.[30] Thus, synthetic patches (PTFE and Dacron) were being developed to overcome the autologous vein shortcomings. These synthetic patches had obvious strengths such as readily available, durable against aneurysmal formation and patch rupture, and less surgical time since the autologous vein is preserved.[43] Yet, these synthetic patches are not without its shortcomings. Both Dacron and PTFE have an increased risk of infection compared to autologous vein, suture bleeding with PTFE use, and prolonged hemostasis time. Efforts have been made to reduce the bleeding risks with these synthetic patches, such as the use of collagen-impregnated knitted Dacron and hemostatic modified PTFE.[60] The results have been promising; however, the superiority of the material still cannot be achieved based on the recent meta-analysis of randomized controlled trials.[69] Biomaterial patches, such as bovine pericardium, are quite popular because they are widely accessible, durable, biocompatible, and allow for immediate ultrasound usage following implantation. This material is widely used in cardiovascular surgery since it has smooth non-thrombogenic surface and excellent hemocompatibility.[15] Unfortunately, reports on possibility of bovine spongiform encephalopathy have decreased its popularity.[38] Nevertheless, its biocompatible characteristic has been proven by Edenfield et al. who conducted an analysis of 70,987 CEA procedures within Vascular Quality Initiative database, where bovine pericardium had lower rates of postoperative events and 1-year restenosis compared to other patch materials.[13] Another biomaterial that has been used clinically is biologic extracellular matrix from porcine small intestinal submucosa. This patch material is biodegradable, in a sense that the host tissue will replace the patch material overtime. Yet, the outcome of this patch has only been reported by a single-center study; thus, further research examining this particular material is needed.[85]
| No. | Study | Material | Group | Subjects | Length of follow-up | Complications | Fulfill the ideal criteria |
|-----|-------|----------|-------|----------|--------------------|---------------|---------------------------|
| 1   | McCready et al. (2021) | CorMatrix (Porcine SIS) | Biomaterial | 275 | 72 months (range: 49–85 months) | Nine had postoperative stroke, 13 resurgery due to restenosis, one resurgery due to bleeding, one pseudoaneurysm | Resistant to infection, durable, low risk of thrombosis |
| 2   | McCready et al. (2005) | CorMatrix (Porcine SIS) | Biomaterial | 76 | 4–6 weeks, 6 months, yearly | 2 had postoperative stroke, 1 cervical hematoma, three resurgery due to restenosis, seven pseudoaneurysm | Durable, biodegradable, provides patency, resistant to infection, resist suture bleeding, easy to handle |
| 3   | Ladowski and Ladowski (2011) | Bovine pericardium | Biomaterial | 775 | 19.2±16.8 months | 24 arteries had significant stenosis, two had critical stenosis; four patients had cervical hematoma, five patients had perioperative stroke | Readily available, resistant to infection, low cost, less bleeding |
| 4   | Mannheim et al. (2005) | Polyester urethane | Synthetic | 206 | 2.5–5 years (median: 2 years) | Five had TIA, three had stroke, five had postoperative bleeding, one had infection, five had cranial nerve damage, 13 had recurrent stenosis | Low restenosis rate |
| 5   | AbuRahma et al. (2005) | Modified polytetrafluoroethylene (PTFE) | Synthetic | 187 | 21 months (range: 1–48 months) | Three had stroke, seven had TIA, two had cervical hematomas, nine had cranial nerve injury, one had infections, six had>70% restenosis (two had resurgery) | Readily available, prevent pseudoaneurysm, low rate of thrombosis, low rate of neurologic complication, low rate of restenosis |
| 6   | AbuRahma et al. (2001) | Collagen-impregnated Dacron (Hemashield) | Synthetic | 144 | 12 months | TIA+Stroke in 12% of patients, recurrent stenosis>50% in 21% | No |
| 7   | Archie (1987) | Saphenous vein | Autologous | 50 CEA | 6–18 months | No complications reported | Provide endothelialized surface, low turbulence, prevent restenosis, and early post thrombosis |
| 8   | Archie (1986) | Vein patch | Autologous | 100 | 1 year | No complications reported | Nonthrombogenic, easy to handle, resist infection |
| 9   | Biasi et al. (2002) | Bovine pericardium | Biomaterial | 323 | 108 months | Five had major perioperative cerebrovascular incident, three deaths, four had resurgery | Resistant to infection, less bleeding, low rate of restenosis, easy to handle |
| 10  | Biasi et al. (1996) | Bovine pericardium | Biomaterial | 49 | 12–30 months | Three have cranial nerve palsies, one had infection, two had significant restenosis | Easy to handle, hemocompatible, no immunologic reaction |

(Contd...)
| No. | Study                          | Material                          | Group            | Subjects | Length of follow-up | Complications                                                                 | Fulfill the ideal criteria                                                                 |
|-----|-------------------------------|-----------------------------------|------------------|----------|---------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|
| 11  | Danikas et al. (2001)         | Double-layer saphenous vein       | Autologous       | 168      | 3–74 months         | Two had early postoperative neurologic deficit                                  | Durable, prevent pseudoaneurysm, great mechanical resistance                               |
| 12  | Ricco et al. (2000)           | Polyester collagen                | Synthetic        | 207      | 726 days (median)   | Three postoperative deaths, one had cervical hematoma complicated with stroke, four had postoperative occlusion, restenosis rate 5% at 2 years and 12.1% at 3 years | Low turbulence, hemocompatible, prevent intimal hyperplasia, easy handling, less bleeding, durable, provides early patency |
| 13  | Meyer and Windschitl (1998)   | Collagen-impregnated Dacron       | Synthetic        | 146      | 1–3 years           | Two had stroke, two had RIND, two had cerebral hemorrhage, two had recurrent stenosis, one had graft infection | Prevent restenosis, durable                                                                 |
| 14  | Eikelboom et al. (1998)       | Saphenous vein                    | Autologous       | 67       | 20 months           | Two had >50% restenosis                                                        | Low restenosis rate                                                                         |
| 15  | Plestis et al. (1996)         | Vein patch                        | Homologous       | 837      | 1–132 months (mean 61 months) | Eight perioperative deaths, 27 had cervical hematomas, two had cranial nerve injury. Long term: neurologic complication in 20 patients, recurrent stenosis in 24 arteries | Low cost, hemocompatible, ready availability                                                  |
| 16  | Perler et al. (1995)          | Dacron                            | Synthetic        | 115      | 1–49 months (mean 16.8 months) | One death, two perioperative stroke, residual stenosis 4.5%, and recurrent stenoses 4.8%. Perioperative complications: 9.2% cardiac, neck hematoma 4.2%, and cranial nerve injury 4.2% | Low restenosis rate and pseudoaneurysm                                                       |
| 17  | Rhodes (1995)                 | Expanded polytetrafluoroethylene | Synthetic        | 753      | 41.4 months (0–197 months) | Six deaths, seven had nonfatal strokes, and 19 had hemorrhages. Recurrent stenosis in 84 (8.9%), 28 (3.7%) needed surgery. Two postoperative infections | Readily available, low rate of restenosis, prevent pseudoaneurysm, great mechanical resistance |
| 18  | Myers et al. (1994)           | Saphenous vein                    | Autologous       | 99       | 54.8–66.2 months    | One had TIA, one had major strike, four had cranial nerve dysfunction, and one had resurgery. Long term: 11 had restenosis, eight had stroke, one had resurgery | No                                                                                           |
| 19  | Katz et al. (1994)            | Expanded polytetrafluoroethylene | Synthetic        | 43       | 29.2 months         | One had major stroke, one had TIA, one had infection                            | Low restenosis rate and neurologic deficit                                                  |

(Contd...)
In our review, the most frequently selected ideal criteria were hemocompatibility, since a thrombogenic substance might induce postoperative stroke, resulting in severe morbidity for the patients. After implantation of vascular patch, plasma protein will be absorbed immediately; they contain binding sites for integrin receptors, which can be found on platelets and many cells. Platelets may become activated as a result of adhesion to these receptors. An endothelialized surface will reduce the activation of platelets significantly, since endothelialized surface can act as physiological layer that can adapt to hemodynamic stresses of the carotid artery. At present, available synthetic material cannot provide this characteristic; thus, biomaterial patches that allow host tissue endothelialization are being developed.

Resistance to infection is also important in providing a safe patch angioplasty CEA. Braided sutures in the synthetic patches can trap bacteria in their interstices, thus providing nidus of infection. Synthetic patches such as PTFE have been modified using monofilament sutures to eliminate this risk. However, the number of infections in synthetic patches is still considerably higher than other materials. Biomaterial patches and autologous vein have been extensively reported to have a low risk of infection; consequently, the creation of materials with this capability is required. We provide a simplified history timeline of the development of patch angioplasty material.[38] This simplified timeline was made to help readers to understand the dynamic changes of the ideal criteria. The finding of new material will create new ideal criteria, and the advancement in the vascular studies will demand a more reliable patch angioplasty material in the future.

Limitations

Our study focused on patch material as a main contributor for a successful CEA procedure. However, we cannot disregard other factors that may contribute to post-CEA complications. One of our proposed ideal criteria and the main goal of any carotid artery stenosis intervention are prevention of restenosis. Although patch material is knowingly affected restenosis rate, arterial intervention itself can promote restenosis. Other factors in patch angioplasty CEA that may increase restenosis rate are surgical technique, patch width, location of arteriotomy, and carotid artery biomechanics.

Future directions

Historically, the characteristics of patch angioplasty which were desired are those with low risk of pseudoaneurysm, prevent rupture, and readily available, since autologous vein cannot provide these characteristics. Synthetic materials and biomaterials are being developed to solve these problems. However, with the use of these foreign materials, several problems ensued. Synthetic materials such as PTFE and Dacron are still at risk for infection, can be thrombogenic, and had prolonged hemostasis time. Biomaterials such as bovine pericardium and biologic extracellular matrix from porcine are desired to overcome the shortcomings of the synthetic materials. Unfortunately, recent systematic review
and meta-analysis still cannot provide evidence the clinically available biomaterials are superior than the synthetic or the autologous ones.[49]

Development of tissue-engineered patch angioplasty is hoped to provide a patch material that can fulfill all of the proposed ideal criteria. The advantage of tissue engineered patch angioplasty is providing a material that integrates with host tissue and has characteristic like a native vessel; thus, the desired ideal criteria can be achieved. One of the most promising tissue-engineered vascular tissues is by nanofiber composites, which combine natural and synthetic polymers.[40] Biomaterials such as collagen, gelatin, chitosan, and elastin have great biocompatibility to the native vessel. However, these materials had poor mechanical properties.[17] Addition of synthetic degradable polymer can overcome the drawbacks of biomaterial, since it can be synthesized flexibly and had excellent mechanical properties. In vitro investigations have previously demonstrated the superiority of these materials. Some in vivo experiments have also been conducted with these materials, demonstrating the tremendous potential of nanofiber composites.[37,40] No single composites have been approved for clinical use yet, thus further research developing these materials are essential for the creation of the ideal patch material.

CONCLUSION

This review provided 10 ideal criteria that can be used to help surgeons to choose a material for patch angioplasty CEA. Up until this day, material than possesses all of the 10 criteria has not yet been found. The ideal criteria in this review serve as foundation in the development of the ideal patch angioplasty material for CEA procedure.

Disclosures

The authors have no relevant financial or nonfinancial interest to disclose.

Declaration of patient consent

Patients’ consent not required as there are no patients’ in this study.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. AbuRahma AF, Robinson PA, Hannay RS, Hudson J, Cutlip L. Prospective controlled study of carotid endarterectomy with hemashield patch: Is it thrombogenic? Vasc Surg 2001;35:167-74.
2. AbuRahma AF, Stone PA, Welch CA, Hofeldt MJ, Hass SM, Perry W. Prospective study of carotid endarterectomy with modified polytetrafluoroethylene (ACUSEAL) patching: Early and late results. J Vasc Surg 2005;41:789-93.
3. Archie JP Jr. Prevention of early restenosis and thrombosis-occlusion after carotid endarterectomy by saphenous vein patch angioplasty. Stroke 1986;17:901-5.
4. Archie JP Jr. The geometry and mechanics of saphenous vein patch angioplasty after carotid endarterectomy. Tex Heart Inst J 1987;14:395-400.
5. Avrahami I, Raz D, Bash O. Biomechanical aspects of closing approaches in postcarotid endarterectomy. Comput Math Methods Med 2018;2018:4517652.
6. Bekelis K, Moses Z, Missios S, Desai A, Labropoulos N. Indications for treatment of recurrent carotid stenosis. Br J Surg 2013;100:440-7.
7. Biasi GM, Mingazzini P, Baronio L, Sampaolo A. Processed bovine pericardium as patch angioplasty for carotid endarterectomy: A preliminary report. Cardiovasc Surg 1996;4:848-52.
8. Biasi GM, Sternjakob S, Mingazzini PM, Ferrari SA. Nine-year experience of bovine pericardium patch angioplasty during carotid endarterectomy. J Vasc Surg 2002;36:271-7.
9. Bonati LH, Gregson J, Dobson J, McCabe DJH, Nederkoorn PJ, van der Worp HB, et al. Restenosis and risk of stroke after
stenting or endarterectomy for symptomatic carotid stenosis in the International Carotid Stenting Study (ICSS): Secondary analysis of a randomised trial. Lancet Neurol 2018;17:587-96.

7. Wolff M, Westaby S, Bower JS, Craggs NJ. Duplex ultrasonography and ultrasound-guided intervention for carotid stenosis. Br J Surg 1994;81:430-4.

8. Roldan-Gandarias R, Díaz-Borges L, Vargas-Carrillo AM, et al. A systematic review of carotid artery stenting for refractory carotid stenosis. J Vasc Interv Radiol 2014;25:58-67.

9. Nield J, Kohley R, Duffin P, et al. Immediate and late results of endarterectomy and stenting for internal carotid artery stenosis. J Vasc Surg 2000;31:797-807.

10. Bond R, Rerkasem K, Naylar AR, Aburahma AF, Rothwell PM. Systematic review of randomized controlled trials of patch angioplasty versus primary closure and different types of patch materials during carotid endarterectomy. J Vasc Surg 2004;40:1126-35.

11. Clagett GP, Patterson CB, Fisher DF Jr, Fry RE, Eidt JE, Humble TH, et al. Vein patch versus primary closure for carotid endarterectomy. A randomized prospective study in a selected group of patients. J Vasc Surg 1989;9:213-23.

12. Danikas D, Schmeler KM, Ginalis EM, Stratoulias C, Shorten SM, Constantinoopoulos G. Double-layer everted saphenous vein patch angioplasty for carotid endarterectomy. Vasc Surg 2001;35:259-61.

13. De Letter JA, Moll FL, Welten RJ, Eikelboom BC, Ackerstaff RG, Vermeulen FE, et al. Benefits of carotid patching: A prospective randomized study with long-term follow-up. Ann Vasc Surg 1994;8:54-8.

14. Eastcott HH, Pickering GW, Rob CG. Reconstruction of internal carotid artery in a patient with intermittent attacks of hemiplegia. Lancet 1954;267:994-6.

15. Edenfield L, Blazick E, Eldrup-Jorgensen J, Healey C, Hendrikse J, Halliday A, et al. Outcomes of carotid endarterectomy for the performance of carotid endarterectomy. J Vasc Surg Res 2021;262:21-6.

16. Eikelboom BC, Ackerstaff RG, Hoeneveld H, Ludwig JW, Tewuwen C, Vermeulen FEE, et al. Benefits of carotid patching: A randomized study. J Vasc Surg 1988;7:240-7.

17. Gunn J, Zhang M. Polyblend nanofibers for biomedical applications: Perspectives and challenges. Trends Biotechnol 2010;28:189-97.

18. Hans SS, Girishkumar H, Hans B. Venous patch grafts and carotid endarterectomy. A critical appraisal. Arch Surg 1987;122:1134-8.

19. Howard G, Roubin GS, Jansen O, Hendrikse J, Halliday A, Fraedrich G, et al. Association between age and risk of stroke or death from carotid endarterectomy and carotid stenting: A meta-analysis of pooled patient data from four randomised trials. Lancet (London, England) 2016;387:1305-11.

20. Huizing E, Vos CG, Hulsebos RG, van den Akker PJ, Borst GJ, Ünlü Ç. Patch angioplasty or primary closure following carotid endarterectomy for symptomatic carotid artery stenosis. Surg J (N Y) 2018;4:e96-101.

21. Huizing E, Vos CG, van den Akker PJ, Schreve MA, de Borst GJ, Ünlü Ç. A systematic review of patch angioplasty versus primary closure for carotid endarterectomy. J Vasc Surg 2019;69:1962-74.e4.

22. Kamenskij AV, Mactaggart JN, Pipinos II, Gupta PK, Dzenis YA. Hemodynamically motivated choice of patch angioplasty for the performance of carotid endarterectomy. Ann Biomed Eng 2013;41:263-78.

23. Katz D, Snyder SO, Gandhi RH, Wheeler JR, Gregory RT, Gayle RG, et al. Long-term follow-up for recurrent stenosis: A prospective randomized study of expanded polytetrafluoroethylene patch angioplasty versus primary closure after carotid endarterectomy. J Vasc Surg 1994;19:198-203.

24. Knight BC, Tait WF. Dacron patch infection following carotid endarterectomy: A systematic review of the literature. Eur J Vasc Endovasc Surg 2009;37:140-8.

25. Ladowski JM, Ladowski JS. Retrospective analysis of bovine pericardium (Vascu-Guard) for patch closure in carotid endarterectomies. Ann Vasc Surg 2011;25:646-50.

26. Lal BK, Beach KW, Roubin GS, Lutsep HL, Moore WS, Malas MB, et al. Restenosis after carotid artery stenting and endarterectomy: A secondary analysis of CREST, a randomised controlled trial. Lancet Neurol 2012;11:755-63.

27. Leal BBJ, Wakabayashi N, Oyama K, Kamiya H, Braghirioli DI, Pranke P. Vascular tissue engineering: Polymers and methodologies for small caliber vascular grafts. Front Cardiovasc Med 2020;7:592361.

28. LeGrand DR, Linehan RL. The suitability of expanded PTFE for carotid patch angioplasty. Ann Vasc Surg 1990;4:209-12.

29. Li X, Guo Y, Ziegler KR, Model LS, Eghbalieh SD, Breens RA, et al. Current usage and future directions for the bovine pericardial patch. Ann Vasc Surg 2011;25:561-8.

30. Malas M, Glebova NO, Hughes SE, Voeks JH, Qazi U, Moore WS, et al. Effect of patching on reducing restenosis in the carotid revascularization endarterectomy versus stenting trial. Stroke 2015;46:757-61.

31. Mannheim D, Wellner B, Vahadim E, Karmeli R. Carotid endarterectomy with a polyurethane patch versus primary closure: A prospective randomized study. J Vasc Surg 2005;41:403-7.

32. Marsman MS, Witterslev J, Jahrome AK, Gluud C, Moll FL, Keus F, et al. Carotid endarterectomy with patch angioplasty versus primary closure in patients with symptomatic and significant stenosis: A systematic review with meta-analyses and trial sequential analysis of randomized clinical trials. Syst Rev 2021;10:139.

33. Masang Ban Bolly H, Faried A, Laurens Jembise T, Fuad Wirakusumah F, et al. The ideal selection criteria for duraplasty material in brain surgery: A review. Interdiscip Neurosurg Adv Tech Case Manag 2020;22:100800.

34. McCreary RA, Hodde J, Irwin RJ, Coffey AC, Divelbiss JL, Bryant MA, et al. Pseudoaneurysm formation in a subset of patients with small intestinal submucosa biologic patches after carotid endarterectomy. J Vasc Surg 2005;41:782-8.

35. McCreary RA, Kiell CS, Chugh AR, Rapp BM, Webb TH, Barksdale A, et al. Long-term results with cormatrix extracellular matrix patches after carotid endarterectomy. J Surg Res 2021;262:21-6.

36. Messas E, Goudet G, Halliday A, Sitruk J, Mirault T, Khider L, et al. Management of carotid stenosis for primary and secondary prevention of stroke: State-of-the-art 2020: A critical review. Eur Heart J Suppl 2020;22:M35-42.

37. Meyer FB, Windschitl WL. Repair of carotid endarterectomy with a polyurethane patch versus primary closure: A prospective randomized study. J Vasc Surg 1990;4:209-12.

38. Muto A, Nishibe T, Dardik H, Dardik A. Patches for carotid endarterectomy. J Vasc Surg 1998;122:1134-8.

39. Myers SI, Valentine RJ, Chervu A, Bowers BL, Clagett GP. Management of carotid stenosis for primary stroke prevention: Current guidelines and future directions. J Vasc Surg 2009;50:206-13.

40. Myers SI, Valentine RJ, Chervu A, Bowers BL, Clagett GP. Saphenous vein patch versus primary closure for carotid endarterectomy: Long-term assessment of a randomized approach. J Vasc Interv Radiol 2020;31:1127-35.
Suroto, et al.: Selection criteria for patch angioplasty

prospective study. J Vasc Surg 1994;19:15-22.
40. Obregón R, Ramón-Azcón J, Ahadian S. In: Ramalingam M, Ramakrishna S. editors. Nanofiber Composites in Blood Vessel Tissue Engineering. Sawston, United Kingdom: Woodhead Publishing, 2017. p. 483-506.
41. Perler BA, Ursin F, Shanks U, Williams GM. Carotid Dacron patch angioplasty: Immediate and long-term results of a prospective series. Cardiovasc Surg 1995;3:631-6.
42. Plestis KA, Kantis G, Haygood K, Earl N, Howell JF. Carotid endarterectomy with homologous vein patch angioplasty: A review of 1006 cases. J Vasc Surg 1996;24:109-19.
43. Ren S, Li X, Wen J, Zhang W, Liu P. Systematic review of randomized controlled trials of different types of patch materials during carotid endarterectomy. PLoS One 2013;8:e55050.
44. Rerkasem K, Rothwell PM. Systematic review of randomized controlled trials of patch angioplasty versus primary closure and different types of patch materials during carotid endarterectomy. Asian J Surg 2011;34:32-40.
45. Rhodes VJ. Expanded polytetrafluoroethylene patch angioplasty in carotid endarterectomy. J Vasc Surg 1995;22:724-30.
46. Ricco JB, Bouin-Pineau MH, Demarque C, Suy R, Kerdiles Y, Garbé JF, et al. The role of polyester patch angioplasty in carotid endarterectomy: A multicenter study. Ann Vasc Surg 2000;14:324-33.
47. Sarkar S, Sales KM, Hamilton G, Seifalian AM. Addressing thrombogenicity in vascular graft construction. J Biomed Mater Res B Appl Biomater 2007;82:100-8.
48. Stone PA, Srivastava M, Campbell JE, Mousa AY, Hass SH, Kazmi H, et al. A 10-year experience of infection following carotid endarterectomy with patch angioplasty. J Vasc Surg 2011;53:1473-7.
49. Texakalidis P, Giannopoulos S, Charisis N, Giannopoulos S, Karasavvidis T, Koullias G, et al. A meta-analysis of randomized trials comparing bovine pericardium and other patch materials for carotid endarterectomy. J Vasc Surg 2018;68:1241-56.e1.

How to cite this article: Suroto NS, Rantam FA, Al Fauzi A, Widiyanti P, Turchan A, Pangaribuan V. Selection criteria for patch angioplasty material in carotid endarterectomy. Surg Neurol Int 2022;13:362.

SUPPLEMENTARY

| No. | Databases | Search terms | Total |
|-----|-----------|--------------|-------|
| 1   | PubMed    | “Carotid endarterectomy” (Title/Abstract ) and (“patch” [Title/Abstract] or “graft” [Title/Abstract]) | 637   |
| 2   | Scopus    | TITLE-ABS-KEY ([carotid] and [endarterectomy] and [patch or graft] AND ”clinical trial” ) | 147   |